No Data
$DTIL Stock Is up 13% Today. Here's What We See in Our Data.
Precision BioSciences Gets FDA Fast Track Label for PBGENE-HBV
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Express News | Precision BioSciences Receives U.S. FDA Fast Track Designation for Pbgene-Hbv, a First-in-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
JonesTrading Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $30
Promising Developments in Precision BioSciences' Gene Editing Programs Drive Buy Rating
